Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIAsp 30 Dosage Split Regimens in Chinese T2D
NCT01278160Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2011
- Primary completion
- Sep 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of biphasic insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in Glycosylated Haemoglobin A1c From Baseline at 16 weeks. Started Jan 2011; status: completed.
02
Drugs
biphasic insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01278160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01278160.